Novel Approaches towards Targeted Head and Neck Cancer Therapies
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 1009
Special Issue Editor
Interests: head and neck cancer; cancer stem cells; biomarkers of treatment response; 3D tumor models; genetic and epigenetics of cancer cells; cancer metabolism EditInterests:
Special Issue Information
Dear Colleagues,
Head and neck cancer is often a highly malignant disease that is etiologically and genetically complex, and notoriously difficult to treat. Recent advances in our understanding of head and neck cancer biology have prompted us to compile this Special Issue. The research helping to uncover the unique properties of head and neck cancer has not only initiated the development of targeted therapies (therapies targeted at specific, upregulated signaling pathways and/or unique mutations frequently present in the particular cancer), such as EGFR-inhibitors and, to a certain extent, VEGF inhibitors, but has also helped to improve the efficacy of both classical chemotherapy protocols as well as radiotherapy. This Special Issue aims to gather manuscripts advancing our general knowledge of head and neck cancer biology, the development of novel therapies, as well as the communication on progress/improvement of classical therapies, including clinical trials.
Dr. Emilia Wiecheć
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EGFR
- VEGFR
- RET
- MET
- PI3K
- radiotherapy
- chemotherapy
- immunotherapy
- HPV
- preclinical HNSCC model
- biomarkers of treatment response
